Helix BioPharma Stock Forward View - Polynomial Regression
| HBP Stock | CAD 1.71 0.02 1.18% |
Helix BioPharma Corp's Polynomial Regression reference page covers the model's projected value and error measures from recent price data. The forecast output and associated deviation metrics are shown for informational use.
The Polynomial Regression forecasted value of Helix BioPharma Corp on the next trading day is expected to be 1.64 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.35.A single variable polynomial regression model attempts to put a curve through the Helix BioPharma historical price points. Mathematically, assuming the independent variable is X and the dependent variable is Y, this line can be indicated as: Y = a0 + a1*X + a2*X2 + a3*X3 + ... + am*Xm All Polynomial Regression forecast figures shown for Helix BioPharma Corp are reference data reflecting model output based on available historical prices. Polynomial Regression Price Forecast For the 26th of March
Given 90 days horizon, the Polynomial Regression forecasted value of Helix BioPharma Corp on the next trading day is expected to be 1.64 with a mean absolute deviation of 0.09 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 5.35 .Please note that although there have been many attempts to predict Helix Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Helix BioPharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Helix BioPharma | Helix BioPharma Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Helix BioPharma Corp uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. No forecasting approach has been shown to beat all others over time. Investors should treat any model output as a guide, not a guarantee.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Polynomial Regression forecasting method's relative quality and the estimations of the prediction error of Helix BioPharma stock data series using in forecasting. Note that when a statistical model is used to represent Helix BioPharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.6904 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0877 |
| MAPE | Mean absolute percentage error | 0.0441 |
| SAE | Sum of the absolute errors | 5.3505 |
Other Forecasting Options for Helix BioPharma
Bollinger Bands applied to Helix Stock price data measure how far Helix has deviated from its recent average relative to its own volatility. This distinction drives the choice of forecasting model applied to Helix BioPharma's price data.Helix BioPharma Related Equities
The stocks listed below are peers of Helix BioPharma within the Health Care space and offer context for ranking and strength. Checking Helix BioPharma against peers on P/E, margins, and return on equity helps put its position in context. Persistent outperformance or underperformance by specific peers relative to Helix BioPharma often signals structural advantages or weaknesses. This type of review is most useful when done often to track how positions shift over time.
| Risk & Return | Correlation |
Helix BioPharma Market Strength Events
For investors tracking Helix BioPharma Corp, market strength indicators offer quantitative evaluation of stock behavior. These indicators add context to timing decisions around Helix BioPharma Corp positions.
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 1.71 | |||
| Day Typical Price | 1.71 | |||
| Price Action Indicator | 0.01 | |||
| Period Momentum Indicator | 0.02 |
Helix BioPharma Risk Indicators
Analyzing Helix BioPharma's basic risk indicators provides investors with a structured view of the risk-return trade-off for helix stock. By identifying the level of risk embedded in Helix BioPharma's investment, investors can make informed decisions about position sizing.
| Mean Deviation | 3.24 | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.64 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Helix BioPharma
Story coverage around Helix BioPharma Corp often expands when market conditions, narrative momentum, or risk-adjusted performance make the security more visible to investors. A disciplined read of coverage separates durable relevance from temporary noise.
Other Macroaxis Stories
Macroaxis story coverage is designed for a broad investing audience that ranges from self-directed traders to advisers, researchers, and institutional market participants. The content is intended to support people who want a more structured path from headline information to portfolio action.
Story Categories
Currently Trending Categories
Helix BioPharma Short Properties
Reviewing short-oriented indicators for Helix BioPharma Corp is useful because long and short participants often create very different signals for timing and volatility. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 55.7 M | |
| Cash And Short Term Investments | 65 K |
More Resources for Helix Stock Analysis
Other Information on Investing in Helix Stock
The ratio set for Helix BioPharma connects key financial figures across reports. These metrics link profitability, liquidity, and valuation signals.